Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07688304

The Abuse Liability of IQOS Heated Tobacco Products Among Adults Who Smoke

This clinical trial aims to evaluate user sensory experiences and smoking behavior when using IQOS heated tobacco products (HTPs) among adults who smoke cigarettes.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Conditions

Age range

21 year–65 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Ohio State University Comprehensive Cancer Center

Columbus, Ohio, 43210, United States

Location contact

Alayna P. Tackett, PhD

CONTACT

[email protected]

844-744-2447

Alayna P. Tackett, PhD

PRINCIPAL_INVESTIGATOR

About this study

PRIMARY OBJECTIVES:

I. Assess the abuse liability (appeal and sensory effects) of IQOS. II. Examine the puffing topography of IQOS.

SECONDARY OBJECTIVES:

I. Evaluate the impact of flavor on the sensory effects, appeal, and puffing topography of IQOS.

II. Evaluate the effect of perceived harm on IQOS use behavior.

EXPLORATORY OBJECTIVE:

I. Examine acute changes to pulmonary health associated with IQOS use.

OUTLINE: Participants are randomized to 1 of 2 arms.

ARM I: Participants use IQOS HeatSticks (flavor matched to their usual cigarette) as much as desired (ad lib) over 60 minutes during laboratory visit 1. At least forty-eight hours later, participants smoke their usual brand cigarette (UBC) ad lib over 60 minutes during laboratory visit 2.

ARM II: Participants smoke their UBC ad lib over 60 minutes during laboratory visit 1. At least forty-eight hours later, participants use IQOS HeatSticks (flavor matched to their usual cigarette) ad lib over 60 minutes during laboratory visit 2.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Adults 21-65 years
  • Adults who smoke (defined as ≥ 5 days weekly use of either menthol or non-menthol cigarettes over the past 3 months)
  • Willing to provide informed consent and abstain from using nicotine products 12 hours before each visit
  • Willing to bring UBC to each study visit
  • Read, write and speak English

Exclusion criteria

  • Current use of other non-combustible nicotine products (e.g., electronic [e]-cigarettes, HTPs; [defined as ≥ 5 days weekly use in the past 30 days])
  • Planning to quit nicotine use and/or use of any smoking cessation medication in the past 30 days
  • Current diagnosis of any lung diseases (e.g., asthma, cystic fibrosis, or chronic obstructive pulmonary disease)
  • Self-reported unstable or significant psychiatric conditions (past/stable conditions will be allowed)
  • History of cardiac event or distress within the past 3 months
  • Deaf, hard of hearing, or have a severe motor disability
  • Are currently pregnant, planning to become pregnant, or breastfeeding (urine pregnancy test will be completed at each visit throughout the study)

Treatment and study plan

Smoking Behavioral Research (IQOS)

Behavioral

Use IQOS HeatSticks (flavor matched to the participant's usual cigarette)

Smoking Behavioral Research (UBC)

Behavioral

Smoke UBC

Primary outcomes

  1. Product Appeal

    Time frame: Minute 5 of product use session, Minute 35 of product use session, Minute 60 of product use session

    Participants will complete the Appeal and Sensory Quality questionnaire. This questionnaire will ask participants to rate each study product for appeal characteristics such as liking, willingness to use again, flavor intensity, pleasantness of taste, etc. on a scale of 0 (not at all) - 100 (extremely). Higher scores indicate greater liking, willingness to use again, flavor intensity, etc.

  2. Product Sensory Attributes

    Time frame: Minute 5 of product use session, Minute 35 of product use session, Minute 60 of product use session

    Participants will rate sensory attributes using the Appeal and Sensory Quality questionnaire. This questionnaire will ask participants to rate each study product for sensory attributes such as harshness, coolness, sweetness, etc. on a scale of 0 (not at all) - 100 (extremely). Higher scores indicate greater harshness, coolness, sweetness, etc.

  3. Economic demand breakpoint

    Time frame: Minute 60 of product use session

    The price point at which a participant is no longer willing to pay for a stick of the study product will be determined by using a cigarette purchase task questionnaire.

  4. Satisfaction and psychological reward

    Time frame: Minute 5 of product use session, Minute 35 of product use session, Minute 60 of product use session

    Satisfaction and psychological reward of study product use will be measured by the Modified Cigarette Evaluation Questionnaire (mCEQ). The mCEQ asks questions relating to satisfaction of using the study product on a scale from 0 (Not at all) - 6 (Extremely).

  5. Abuse Liability Via Puff Topography - Total Smoking Time

    Time frame: Minute 60 of product use session

    Will be measured with a topography device that records frequency, duration, and flow rate of cigarette puffs. These measures are combined to inform overall cigarette puff behavior.

  6. Abuse Liability Via Puff Topography - Average Puff Duration

    Time frame: Minute 60 of product use session

    Will be measured with a topography device that records frequency, duration, and flow rate of cigarette puffs. These measures are combined to inform overall cigarette puff behavior.

  7. Abuse Liability Via Puff Topography - Average Flow Rate

    Time frame: Minute 60 of product use session

    Will be measured with a topography device that records frequency, duration, and flow rate of cigarette puffs. These measures are combined to inform overall cigarette puff behavior.

  8. Abuse Liability Via Puff Topography - Average Inter-Puff Interval

    Time frame: Minute 60 of product use session

    Will be measured with a topography device that records frequency, duration, and flow rate of cigarette puffs. These measures are combined to inform overall cigarette puff behavior.

  9. Abuse Liability Via Puff Topography - Average Puff Volume

    Time frame: Minute 60 of product use session

    Will be measured with a topography device that records frequency, duration, and flow rate of cigarette puffs. These measures are combined to inform overall cigarette puff behavior.

  10. Craving/withdrawal

    Time frame: Minute 0 before product use session, Minute 5 of product use session, Minute 35 of product use session, minute 60 of product use session

    Nicotine withdrawal and craving symptoms will be measured using the Minnesota Nicotine Withdrawal Scale (MNWS)

Secondary outcomes

  1. Spirometry FEV1

    Time frame: Minute 0 before start of product use session and minute 60 of product use session

    Spirometry will be used to measure forced expiratory volume (FEV1)

  2. Spirometry FVC

    Time frame: Minute 0 before start of product use session, Minute 60 of product use session

    Spirometry will be used to measure forced vital capacity (FVC)

  3. Spirometry FEV1/FVC

    Time frame: Minute 0 before start of product use session, Minute 60 of product use session

    Spirometry will be used to measure FEV1/FVC

  4. Used filter count

    Time frame: Minute 60 of product use session

    Will assess the number of study product consumed

  5. Harm Perception

    Time frame: Minute 60 of product use session

    A harm perception questionnaire will be used to assess the relative and absolute perceived harm of IQOS products.

Study contacts

Contact information is provided by the study sponsor or research team.

The Ohio State University Comprehensive Cancer Center

CONTACT

[email protected]

800-293-5066

Sponsors and collaborators

Lead sponsor

Ohio State University Comprehensive Cancer Center

Other

Collaborators

  • National Cancer Institute (NCI)

Registry information

Official study title

Studying User Sensory Experiences and Smoking Behavior of IQOS Heated Tobacco Products to Improve Harm Reduction Among Adult Cigarette Smokers

Important dates

Study start
2026
Primary completion
2027
Study completion
2027
First posted
Jul 7, 2026
Registry last updated
Jul 7, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.